Analyst Color

CoreWeave Growth Fueled By OpenAI Contracts, Strategic Acquisition, Says Analyst
CoreWeave Growth Fueled By OpenAI Contracts, Strategic Acquisition, Says Analyst
S&P 500 Tests Records Ahead Nvidia Results, MongoDB Rockets: What's Moving Markets Wednesday?
S&P 500 Tests Records Ahead Nvidia Results, MongoDB Rockets: What's Moving Markets Wednesday?
MongoDB Scores Best Day Ever After Earnings Beat—Here's What Wall Street Thinks
MongoDB Scores Best Day Ever After Earnings Beat—Here's What Wall Street Thinks
S&P 500 Tests Records Ahead Nvidia Results, MongoDB Rockets: What's Moving Markets Wednesday?
S&P 500 Tests Records Ahead Nvidia Results, MongoDB Rockets: What's Moving Markets Wednesday?
MongoDB Scores Best Day Ever After Earnings Beat—Here's What Wall Street Thinks
MongoDB Scores Best Day Ever After Earnings Beat—Here's What Wall Street Thinks
Nvidia's Big Test: 5 ETFs That Could Soar—Or Sink—After Earnings
Nvidia's Big Test: 5 ETFs That Could Soar—Or Sink—After Earnings
Why Lululemon's Global Expansion Could Outweigh North America Slowdown
Why Lululemon's Global Expansion Could Outweigh North America Slowdown

Analyst Color Recent News

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst
Summit and Akeso report ivonescimab's survival benefit in lung cancer, boosting approval odds and positioning it as a Keytruda challenger.
Trump Escalates Fed Fight: Fires Governor, Eyes Full Overhaul
Trump Escalates Fed Fight: Fires Governor, Eyes Full Overhaul
Trump's firing of Fed Governor Lisa Cook marks a bold step in reshaping the Fed's future. A fight over independence has begun.
Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker
Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker
HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billion potential and strong fibrosis treatment pipeline.
AI Power Crunch Looms: Can Oklo's Nuclear Reactors Save Data Centers?
AI Power Crunch Looms: Can Oklo's Nuclear Reactors Save Data Centers?
Oklo Inc. (NYSE: OKLO) offers scalable nuclear reactors to address data center power shortage. Analysts rate it a Buy with $92 target.
Snowflake Analyst Remains Bullish Ahead Of Q2 Earnings Release
Snowflake Analyst Remains Bullish Ahead Of Q2 Earnings Release
Snowflake (SNOW) to report Q2 results with 85% positive data points. Analyst expects 25% revenue growth, sees huge market opportunity for company.
Constellation Brands Analyst Turns Bearish As Market Conditions Worsen For Beer, Wine, Gen Z
Constellation Brands Analyst Turns Bearish As Market Conditions Worsen For Beer, Wine, Gen Z
Constellation stock is down 26% YTD, with further risks from Hispanic demographic, alcohol trends, and capacity buildout in Mexico.
Palantir Bears Get Cramer's Blunt Warning: 'Karp Knows All'
Palantir Bears Get Cramer's Blunt Warning: 'Karp Knows All'
Don't underestimate Karp and Palantir's fundamentals. Despite recent dip, bears have not taken over. Analysts amazed by company's growth potential.
Powell's Shift Could Spark A Homebuilder Boom—Investors Are Already Piling In
Powell's Shift Could Spark A Homebuilder Boom—Investors Are Already Piling In
Homebuilder stocks soared after Jerome Powell's dovish pivot. With rates falling and housing demand steady, investors are piling in.
Figma Is A 'Compelling AI Story,' Already Crossing $1 Billion In Revenue
Figma Is A 'Compelling AI Story,' Already Crossing $1 Billion In Revenue
JPMorgan and RBC Capital Markets initiated analyst coverage on Figma, a design software company that recently raised $1.22B in an IPO.
Amazon, Meta Among Early Adopters Of Nvidia's Jetson Thor Robotics Platform
Amazon, Meta Among Early Adopters Of Nvidia's Jetson Thor Robotics Platform
Nvidia stock rises on new robotics platform, analysts predict strong earnings driven by GB200 and Blackwell products, despite China trouble.
Connect With Us
blueskyinstagramlinkedinyoutube
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2025 Benzinga | All Rights Reserved